Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
30th Jul 200812:00 pmPRNStatement re Update Regarding Milestone Payment
25th Jul 200810:57 amPRNHolding(s) in Company
24th Jul 20082:00 pmPRNTiming of AGM and Interim Results
24th Jul 20087:00 amPRNHolding(s) in Company
11th Jul 200812:12 pmPRNStatement re Successful Patent Opposition
1st Jul 20087:00 amPRNDirectorate Change
25th Jun 200812:30 pmPRNResearch Update
25th Jun 20087:00 amPRNAnnual Report and Accounts
24th Jun 20083:50 pmPRNHolding(s) in Company
18th Jun 20081:10 pmPRNHolding(s) in Company
9th Jun 20087:00 amRNSPresentations at upcoming con
5th Jun 20087:00 amPRNHolding(s) in Company
16th May 20082:05 pmPRNHolding(s) in Company
6th May 20089:00 amRNSPresentation at Conference
7th Apr 20084:12 pmRNSHolding(s) in Company
7th Apr 20087:01 amRNSDevelopment Concept Supported
1st Apr 20087:05 amPRNDirector/PDMR Shareholding
31st Mar 20087:49 amPRNDirector/PDMR Shareholding
27th Mar 20082:24 pmPRNHolding(s) in Company
27th Mar 20087:00 amPRNPreliminary Final Results
19th Mar 20082:30 pmPRNNotice of Results
19th Mar 200810:56 amPRNHolding(s) in Company
13th Mar 20082:15 pmPRNRe Agreement
13th Mar 200810:54 amPRNHolding(s) in Company
5th Feb 200811:00 amPRNHolding(s) in Company
31st Jan 20084:25 pmPRNHolding(s) in Company
30th Jan 20087:00 amPRNHolding(s) in Company
23rd Jan 200810:05 amPRNHolding(s) in Company
21st Jan 20084:09 pmPRNHolding(s) in Company
17th Jan 20087:00 amPRNHolding(s) in Company
7th Jan 20087:00 amPRNStatement re Chairman's Letter to Shareholders
2nd Jan 20084:25 pmPRNHolding(s) in Company
2nd Jan 200811:10 amPRNHolding(s) in Company
24th Dec 20077:00 amPRNDirector/PDMR Shareholding
17th Dec 20071:40 pmPRNStatement re Share Price Movement
14th Dec 20074:20 pmPRNHolding(s) in Company
12th Dec 20071:31 pmPRNHolding(s) in Company
4th Dec 20074:23 pmPRNHolding(s) in Company
26th Nov 20074:21 pmPRNHolding(s) in Company
23rd Nov 20073:30 pmPRNHolding(s) in Company
20th Nov 20077:00 amPRNChange of Nomad
19th Nov 20071:00 pmPRNResearch Update
19th Nov 20077:02 amRNSPresentation at Conference
5th Nov 20071:20 pmPRNHolding(s) in Company
2nd Nov 200712:35 pmPRNHolding(s) in Company
2nd Nov 20077:01 amRNSConference Attendance
30th Oct 200710:00 amPRNHolding(s) in Company
29th Oct 20074:15 pmPRNHolding(s) in Company
26th Oct 20074:15 pmPRNHolding(s) in Company
25th Oct 200711:10 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.